Drugs used in Diabetes
Overview
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBL and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2023 to March 2026
Financial Headline Summary Reports
These pdf reports summarise the headline information from the Monthly Financial Headlines, Top 50 BNF Sections and Drugs and Price Concessionary bulletin reports at SICBL, ICB, regional and national level. Copies of this report are available on request via nuth.nyrdtc.rxsupp@nhs.net.
A version of the report showing the data for the 7 commissioning regions with England selected as the focus is shown below.
Time period
April to May 2026
Frequency
Monthly
Respiratory System
Overview
This report looks at prescribing trends in primary care for the Respiratory System at SICBL and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2023 to March 2026
Cardiovascular System
Overview
This report looks at prescribing trends in primary care for the Cardiovascular System at SICBL and ICB level with particular focus on anticoagulants, antiplatelets and lipid-regulating. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for cardiovascular drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2023 to March 2026
Pain Management
Overview
This report looks at prescribing trends in primary care in relation to Pain Management at ICB and Sub Integrated Board location (SICBl) with particular focus on Opioid and Non-opioid analgesics, Neuropathic pain, Antimigraine drugs and Osteoarthritis.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Bi-annually
Data Period
April 2023 to March 2026
Antibacterial drugs
Overview
This report looks at prescribing trends in primary care for antibacterial drugs at SICBL and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2023 to March 2026
Blood Glucose Test Strips – MO opportunities
Overview
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.
This report focuses on the appropriate prescribing and supply of blood glucose and ketone meters and testing strips and has data at SICBL, ICB and Commissioning Region level.
In 2023, NHS England published Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets. This details the recommended meters, strips and lancets, that following evaluation have been determined to have the highest quality and be most cost effective.
NHS England Aim: to utilise the best value blood glucose and ketone meters, and testing strips.
The report is provided to NHS colleagues only, please do not share outside the NHS.
If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.
This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.
Frequency
Quarterly
Data period
April 2023 to March 2026
Antibacterial – MO opportunities
Overview
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.
This report has data at SICBL, ICB and Commissioning Region level and focuses on the antibacterial MO opportunities:
- Reducing course length of antimicrobial prescribing
- Switching intravenous antibiotics to oral
NHS England Aims:
- Reduce course length of antimicrobial prescribing to 5 days for specific common infections, where appropriate: sinusitis, sore throat, COPD infective exacerbation, cough (acute), pneumonia (community-acquired) and otitis media.
- To reduce the number of patients receiving IV antibiotics past the point at which they meet the switch criteria and to reduce the proportion of IV doses.
The report is provided to NHS colleagues only, please do not share outside the NHS.
If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.
Frequency
Quarterly
Data period
April 2023 to March 2026
Antidepressants – MO opportunities
Overview
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.
This report focuses on addressing inappropriate antidepressant prescribing and has data at SICBL, ICB and Commissioning Region level.
NHS England Aim: Reduce inappropriate long-term prescribing and associated spend on antidepressants.
The report is provided to NHS colleagues only, please do not share outside the NHS.
If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.
This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.
Frequency
Quarterly
Data period
April 2023 to March 2026
Drugs for Dementia
Overview
This report looks at prescribing trends in primary care for Drugs for Dementia at SICBL and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QOF registers.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2023 to March 2026